Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: A 2-week, multicenter, randomized, open-label study

Clinical Therapeutics

Volumn 30, Issue PART 1, 2008, Pages 989-1002

  Donohue, James F ^a   Hanania, Nicola A ^b   Ciubotaru, Ronald L ^c   Noe, Les ^d   Pasta, David J ^d   Schaefer, Kendyl ^e   Claus, Raymond ^e   Andrews, William T ^e   Roach, James ^e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d ICON CLINICAL RESEARCH   (United States)

^e DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

asthma; bronchoconstriction; COPD; costs; levalbuterol; racemic albuterol

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVALBUTEROL; SALBUTAMOL; SALMETEROL; THEOPHYLLINE;

ADULT; ANXIETY DISORDER; APNEA; ARTICLE; ASTHMA; BRONCHITIS; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SYMPTOM ASSESSMENT; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HEADACHE; HEALTH STATUS; HEART RATE; HOSPITAL COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; INSOMNIA; LENGTH OF STAY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MENTAL CONCENTRATION; MULTICENTER STUDY; NEBULIZATION; NERVOUSNESS; PAIN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SUBJECT GENERAL WELL BEING SCORE; SYMPTOMATOLOGY; TREATMENT RESPONSE; TREMOR;

ACUTE DISEASE; AGED; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; FEMALE; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; STEREOISOMERISM;

EID: 47249143637     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.06.010     Document Type: Article

References (38)

1. National Health Interview Survey: Research for the 1995-2004 Redesign (1999), National Center for Health Statistics, Hyattsville, Md
2. National Center for Health Statistics. Centers for Disease Control and Prevention. Asthma Prevalence, Health Care Use and Mortality, 2002 (June 3, 2008). http://www.cdc.gov/nchs/products/pubs/pubd/hestats/asthma/asthma.htm Accessed
3. US Dept Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. Chronic Obstructive Pulmonary Disease (June 3, 2008). http://www.nhlbi.nih.gov/health/public/lung/other/copd_fact.pdf Accessed
4. Penn R., Frielle T., McCullough J., et al. Comparison of R-, S-, and RS-aalbuterol interaction with human beta 1- and beta 2-adrenergic receptors. Clin Rev Allergy Immunol. 14 (1996) 37-45
5. Lötvall J., Palmqvist M., Arvidsson P., et al. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol. 108 (2001) 726-731
6. Agrawal D., Ariyarathna K., and Kelbe P. (S)-Albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol. 113 (2004) 503-510
7. Cho S., Hartleroad J., and Oh C. (S)-albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Immunol. 124 (2001) 478-484
8. Pereira A., Mendes E., Ferreira T., and Wanner A. Effect of inhaled racemic and (R)-albuterol on airway vascular smooth muscle tone in healthy and asthmatic subjects. Lung 181 (2003) 201-211
9. Gumbhir-Shah K., Kellerman D., DeGraw S., et al. Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. J Clin Pharmacol. 38 (1998) 1096-1106
10. Maier G., Rubino C., Hsu R., et al. Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma. Pulm Pharmacol Ther. 220 (2007) 534-542
11. Hamilos D., D'Urzo A., Levy R., et al. Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. Ann Allergy Asthma Immunol. 99 (2007) 540-548
12. Qureshi F., Zaritsky A., Welch C., et al. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med. 46 (2005) 29-36
13. Ralston M., Euwema M., Knecht K., et al. Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: A randomized controlled trial. J Emerg Med. 29 (2005) 29-35
14. Milgrom H., Skoner D., Bensch G., et al., for the Levalbuterol Pediatric Study Group. Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol. 108 (2001) 938-945
15. Nelson H., Bensch G., Pleskow W., et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol. 102 (1998) 943-952
16. Nowak R., Emerman C., Schaefer K., et al. Levalbuterol compared with racemic albuterol in the treatment of acute asthma: Results of a pilot study. Am J Emerg Med. 22 (2004) 29-36
17. Nowak R., Emerman C., Hanrahan J., et al., for the XOPENEX Acute Severe Asthma Study Group. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med. 24 (2006) 259-267
18. Gawchik S., Saccar C., Noonan M., et al. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol. 103 (1999) 615-621
19. Carl J., Myers T., Kirchner H., and Kercsmar C. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr. 143 (2003) 731-736
20. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-33): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 120 Suppl (2007) S94-S138
21. Truitt T., Witko J., and Halpern M. Levalbuterol compared to racemic albuterol: Efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 123 (2003) 128-135
22. Pikarsky R., Acevedo R., Farrell T., and Fascia W. Breakthrough treatment rates during a conversion to levalbuterol, tiotropium and breath actuated nebulizers. Chest 128 Suppl (2005) 259 Abstract
23. Pikarsky R., and Acevedo R. Clinical and economic impact resulting from a hospital-wide conversion from racemic albuterol to levalbuterol. Chest 122 Suppl (2002) 25S
24. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects (May 14, 2008). http://www.wma.net/e/policy/b3.htm Accessed
25. Ventolin Inhalation Solution [product information]. In: Sifton D. (Ed). Physicians' Desk Reference (2001), Medical Economics Co, Inc, Montvale, NJ 1055-1057
26. National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the diagnosis and management of asthma (1997), US Dept of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, Md Report no. 97-44051
27. Mahoney E., Jurkovitz C., Chu H., et al., for the Treat Angina with Agrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction (TACTICS-TIMI 18) Investigators. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 288 (2002) 1851-1858
28. Mark D., Nelson C., Anstrom K., et al., for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: Results from the Sudden Cardiac Death in Heart Failure Trial. Circulation 114 (2006) 135-142
29. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for Industry: E9 Statistical Principles for Clinical Trials (1998), FDA, Washington, DC
30. Amend E., Burns B., and Wolfe J. The increased cost of treating patients with levalbuterol is more than offset by a reduction in treatment frequency and associated labor costs. Respir Care 50 (2005) 1552 Abstract
31. Milgrom H. Levosalbutamol in the treatment of asthma. Expert Opin Pharmacother. 7 (2006) 1659-1668
32. Schreck D., and Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med. 23 (2005) 842-847
33. Ozminkowski R., Wang S., and Long S. The impact of nebulized levalbuterol on health care payments for elderly asthma and chronic obstructive pulmonary disease patients in Medicaid plans. Dis Manage Health Outcomes 15 (2007) 41-55
34. Hardasmalani M., DeBari V., Bithoney W., and Gold N. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 21 (2005) 415-419
35. Norman G., Sloan J., and Wyrwich K. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 41 (2003) 582-592
36. White M., and Sander N. Asthma from the perspective of the patient. J Allergy Clin Immunol. 104 (1999) S47-S52
37. Pauwels R., Buist A., Calverley P., et al., for the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease Workshop summary. Am J Respir Crit Care Med. 163 (2001) 1256-1276
38. Gold M., Siegel J., Russell L., and Weinstein M. Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, Inc, New York, NY